Affiliation:
1. Eye Center
2. Far Eastern Federal University
3. Pacific State Medical University
Abstract
Age-related macular degeneration (AMD) is one of the major reasons that cause irreversible vision loss among older people. Over the past two decades, vascular endothelial growth factor (anti-VEGF) inhibitors have been successfully used in the treatment of AMD. In this article, we study a new antivasoproliferative agent brolucizumab for the treatment of exudative AMD forms. The drug has demonstrated its high effectiveness in terms of a more rapid onset of therapeutic effect and the resolution of intraretinal and subretinal exudation.
Publisher
Pacific State Medical University